CureVac’s Stock Journey Concludes Following BioNTech Acquisition

The independent public trading story for CureVac has reached its conclusion. BioNTech’s successful takeover has led to a suspension of the company’s shares. For shareholders, this marks the closing of one chapter, while the new owner immediately faces fresh legal complexities that may impact the strategic rationale behind the acquisition.

A Strategic Acquisition and Immediate Leadership Shift

BioNTech valued the Tübingen-based firm at approximately $1.25 billion in an all-stock transaction. Shareholders received an effective price of about $5.46 per share, representing a 55% premium over CureVac’s three-month average stock price prior to the deal’s announcement. The offer garnered substantial support, with nearly 87% of shares tendered by mid-December. The remaining shares were acquired via a squeeze-out procedure in January.

Concurrent with the deal’s completion, a leadership transition was executed. CureVac’s existing management team has stepped down. BioNTech’s CEO, Ugur Sahin, along with his leadership team, has now assumed control, integrating CureVac’s operations fully into its own structure.

The acquisition secures several key strategic assets for the Mainz-based company:
* CureVac’s manufacturing facility in Tübingen.
* The proprietary “RNA Printer” technology for automated production.
* An extensive patent library and oncology-focused development pipeline.

Trading Halt and Formal Delisting Process

The final act for CureVac’s stock commenced on January 6, when Nasdaq halted trading prior to market open. The final recorded price was set at $4.66 per share—a gain of roughly 40% since the initial takeover announcement in June 2025. The company has filed the necessary paperwork with the U.S. Securities and Exchange Commission (SEC).

Should investors sell immediately? Or is it worth buying CureVac?

The subsequent timeline is clearly outlined: a formal delisting will occur on January 16, 2026. The complete deregistration with the SEC will become effective within the following 90 days.

Emerging Legal Challenges Post-Merger

Shortly after the deal’s finalization, a new challenge emerged for the mRNA sector. On January 6, Bayer filed a lawsuit in the United States against BioNTech, Pfizer, and Moderna. The allegation centers on the infringement of patents held by its subsidiary Monsanto related to mRNA stabilization technology.

As BioNTech is now the legal successor to CureVac and has assumed all existing obligations, this litigation adds a layer of complexity to the integration process. Potential legal costs associated with the dispute could affect the calculated strategic value derived from the transaction.

For former CureVac investors, this development fundamentally alters the risk profile of their holding. They now hold direct shares in BioNTech, exchanging the volatility of a single development-stage biotech stock for the more diversified positioning of the larger acquirer. Their investment focus shifts entirely to the pipeline and operational performance of the new parent company.